| This week's sponsor is TD2. | | | |
Today's Rundown JPM need-to-know: BMS chief's growth promise, Lilly CEO's call to action, J&J's pretty-but-unrealistic tech vision, and more Hung out to dry? Axovant’s terrible JPM week Is bigger better? Highlights from FierceBiotech's Executive Breakfast at JPM J&J chief’s pharma-tech vision is pretty, but it’s certainly not reality: experts Lilly CEO: With pharma friends in high places, it's 'time for action' to ease drug costs In it for the long haul: A chat with Barry Greene Wondering how Teva found room to cut $3B? Look at its past mistakes, CEO says Shire divvies up its operations to prime neuroscience unit for future sale or spinoff After $270M round, BioNTech pens TCR pact with Scancell Biotech stocks fail to lift on so-so J.P. Morgan conference's first day Featured Story | | | Monday, January 8, 2018 Pharma watchers wondered at the lack of big M&A news at the J.P. Morgan Healthcare Conference Tuesday, and biotech investors lamented the lack of a JPM stock bump—but there was no lack of other info to report. Here's the word from two Big Pharma CEOs, Axovant's bad news bunker, and more. |
|
|
| This week's sponsor is Veeva. | | | [Webinar] Tufts eClinical Landscape Study: Q&A with Industry Experts
January 16, 2018 | 2pm ET / 11am PT
Hear expert analysis of the 2017 eClinical Landscape Survey, one of the largest, most in-depth surveys of clinical data management professionals that shows the impact of database build delays on trial timelines, as well as the projected increase of data source usage. Register Now |
Top Stories Wednesday, January 10, 2018 David Hung is the CEO who sold his company, Medivation, to Pfizer for $14 billion. He got the plaudits, a big payday and seemingly a free pass to almost any biopharma job he wanted. Now his decision to join Axovant looks more like a gamble that isn't paying off. Wednesday, January 10, 2018 SAN FRANCISCO—Six panelists representing biotech, pharma and VC discussed the meaning of good science, how money affects a company's behavior and how different players can work together to leverage their respective strengths and deliver therapies to patients. Wednesday, January 10, 2018 The time when pharma fully embraces tech is still very far off, despite some optimistic comments from executives at JPM. So far, in fact, “no one can see it at the moment,” one expert told us. It’s more likely that pharma will get caught flat-footed when a true tech player comes in to disrupt the market. Wednesday, January 10, 2018 Merck & Co.'s top executive said Monday that pricing pressure isn't likely to get worse. But Eli Lilly CEO David Ricks begs to differ. If pharma doesn't do something, "people will do things for us," the helmsman said. Tuesday, January 9, 2018 Alnylam President Barry Greene discusses the retooled Sanofi deal, Alnylam's transition to a commercial-stage company and what's on the horizon in 2018. Tuesday, January 9, 2018 Since new CEO Kåre Schultz rolled out Teva’s $3 billion cost-cutting plan a few weeks back, “some have asked me, ‘how on earth is this possible?’” he said on Monday at the J.P. Morgan Healthcare Conference. One word: structure. Monday, January 8, 2018 Shire has a penchant for making headlines at the J.P. Morgan Healthcare Conference, and it did so again early Monday. Tuesday, January 9, 2018 BioNTech has followed up on its $270 million megaround by striking a deal with Scancell. The alliance gives BioNTech the chance to work with Scancell to discover and characterize T cell receptors (TCRs) and an option to form a license agreement covering the resulting therapeutics. Tuesday, January 9, 2018 Last year, things were pretty quiet out of the J.P. Morgan Healthcare Conference: few deals, few major updates. That seemed to set the tone for much of the year, at least on the M&A front. | This week's sponsor is Protea Biosciences. | | Protea's “BIOPHARMA” Assets Available For Sale in Morgantown, WV (Ch. 11 Debtor) Cancer-Diagnostic Protocols, Lab EQ, & Licenses ($1.15MM Min) Stalking Horse Bid at $1.0MM Already Filed; Sale Hearing Date 01/24/18 Small Molecule Analytics Business, EQ, & Cust. AR + $75.0MM NOLs ($1.0MM Min) All assets to be sold via 363-Sale Auctions (No. Distr. of WV BK Court - Case: 17-1200) Bids are due by January 18, 2018 (Unless Extended) Contact: Jack Teitz, CRO for Additional Information: 412-855-7625 |
Enrollment Showcase | | | Sponsored by: Drexel University Online Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more. |
|
|
Resources Sponsored by: Veeva Systems Regulatory leaders share challenges and best practices from a lack of standardization, manual processes, and fragmented systems. Sponsored by: WCG Selecting the right sites to conduct your clinical trials will determine the success or failure of meeting your enrollment goals. Sponsored by: Veeva Systems Read this guide if you’re a global life sciences company - conducting clinical trials across several countries, or manufacturing and distributing products in multiple regions - to learn five steps to align and improve quality oversight, as well as avoid common mistakes in harmonization initiatives. Presented By: Covance Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives. Presented By: Charles River Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols. Presented By: Catalent Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility. Presented By: Catalent Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology. Presented By: Catalent Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. Drug Development Boot Camp® 2018 November 14-15, 2018 | Boston, MA Drug Approval, Manufacturing Quality & Regulation 2018 | Online TMF Operations: a Quality and Regulatory Approach March 19 - 21, 2018 | Berlin, Germany
Field Service Medical February 26-28, 2018 | Hilton La Jolla, Torrey Pines, CA |
